Pancreatic tumors show high levels of hypoxia.

By A. Koong, Vivek K Mehta, Quynh T. Le, George A. Fisher, D. Terris, J. Brown, A. Bastidas, Mark A. Vierra. International Journal of Radiation Oncology, Biology, Physics, 2000

604 citations recorded by the source corpus.

Subfields: Biotechnology, Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/efc58bb1c3f24480d995f969e24bbd70bc3e3cf0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

1. J. Tatum
2. J. Overgaard

In Cancer Research

1. M. V. Vander Heiden
2. Craig B. Thompson
3. Joshua D. Rabinowitz
4. Ralph J. Deberardinis
5. J. Tatum
6. Hans Clevers
7. D. Tuveson
8. D. Öhlund

In Molecular Biology

1. M. V. Vander Heiden
2. Craig B. Thompson
3. Joshua D. Rabinowitz
4. Hans Clevers
5. R. Vries
6. Meritxell Huch
7. Edwin Cuppen
8. J. Tatum

Citations in the corpus

• KRAS: feeding pancreatic cancer proliferation (2014, neutral): “PDAC exhibits characteristically low vascular density and a dense stromal surrounding that, in addition to hindering the delivery of therapeutics and contributing to overall PDAC aggressiveness [35], aids in the formation of numerous hypoxic regions [35,36].”
• Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. (2015, positive): “Indeed, PDAC tumors, which are characterized by poor vascularization and high interstitial pressure, are typically hypoxic (9, 10).”
• Organoid Models of Human and Mouse Ductal Pancreatic Cancer (2014, methodology): “…intraepithelial neoplasms (PanINs) (Hingorani et al., 2003; Pérez-Mancera et al., 2012) and were used to discover that PDA possesses a deficient vasculature that impairs drug delivery (Erkan et al., 2009; Jacobetz et al., 2013; Koong et al., 2000; Olive et al., 2009; Provenzano et al., 2012).”
• Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy (2006, background): “Similar variability is apparent among studies of prostate cancer (Cvetkovic et al. 2001, Movsas et al. 1999, Movsas et al. 2002, Parker et al. 2004), pancreatic cancer (Koong et al. 2000), rectal cancer (Kallinowski et al. 1995, Mattern et al. 1996), and metastatic melanomas (Lartigau et al. 1997).”